Advances in the Treatment of Diffuse Large B Cell Lymphoma: ADCs, Bispecific Antibodies, CAR T Therapies and Combinations – Enduring Webcast

Description

Program Description

---

DLBCL is the most common subtype of mature B-cell non-Hodgkin’s lymphoma (NHL). Gene expression profiling has identified distinct subtypes within DLBCL based on cell of origin (COO): germinal center B-cell (GCB) subtype and activated B-cell (ABC) subtype.1,2 GCB DLBCL is associated with an improved outcome compared with ABC DLBCL in patients treated with conventional chemoimmunotherapy with R-CHOP. The up-front treatment approach remains the same for both GCB and ABC subtypes. Accurate diagnosis of the DLBCL, appropriate patient selection, and effective management of the unique spectrum of adverse events associated with targeted therapies should be an integral part of managing patients with R/R disease. Referral of appropriate patients for participation in well-designed prospective clinical trials should be considered to facilitate the development of novel chemotherapy-free treatment options.

Intended Audience

---

Hematologists/ oncologists, nurse practitioners, physician assistants, nurses, and other healthcare professionals caring for DLBCL.

Commercial Supporter

---

This activity is supported by an educational grant from ADC Therapeutics America, Inc.